KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Current Deferred Revenue (2016 - 2025)

Historic Current Deferred Revenue for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $553.0 million.

  • Regeneron Pharmaceuticals' Current Deferred Revenue fell 1190.06% to $553.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $553.0 million, marking a year-over-year decrease of 1190.06%. This contributed to the annual value of $553.0 million for FY2025, which is 1190.06% down from last year.
  • According to the latest figures from Q4 2025, Regeneron Pharmaceuticals' Current Deferred Revenue is $553.0 million, which was down 1190.06% from $545.6 million recorded in Q3 2025.
  • Regeneron Pharmaceuticals' 5-year Current Deferred Revenue high stood at $627.7 million for Q4 2024, and its period low was $381.1 million during Q2 2023.
  • Its 5-year average for Current Deferred Revenue is $512.9 million, with a median of $512.2 million in 2021.
  • As far as peak fluctuations go, Regeneron Pharmaceuticals' Current Deferred Revenue tumbled by 3270.35% in 2023, and later skyrocketed by 5376.54% in 2024.
  • Over the past 5 years, Regeneron Pharmaceuticals' Current Deferred Revenue (Quarter) stood at $442.0 million in 2021, then increased by 8.12% to $477.9 million in 2022, then fell by 3.98% to $458.9 million in 2023, then skyrocketed by 36.78% to $627.7 million in 2024, then fell by 11.9% to $553.0 million in 2025.
  • Its Current Deferred Revenue was $553.0 million in Q4 2025, compared to $545.6 million in Q3 2025 and $481.9 million in Q2 2025.